论文部分内容阅读
1文献来源Koeppen H,Yu W,Zha JP,et al.Biomarker analyses from a placebo-controlled phaseⅡstudy evaluating Erlotinib±Onartuzumab in advanced non-small-cell lung cancer:MET expression levels are predictive of patient benefit[J].Clin Cancer Res,2014,Mar 31[E